

Vote-by-mail form

the Ordinary General Meeting of Shareholders of Antibiotice SA held on **26/27.08.2025**

The undersigned _____ [*individual shareholder's full name*], identified by _____ [*identity card*], series _____, number _____, issued by _____, on _____, domiciled in _____, National Identification Number _____,

or

The undersigned _____ [*name of the entity/legal person*], established in _____, registered at the Trade Register Office under no. J _____ Unique Registration Code _____, legally represented by _____ (*)

shareholder on the reference Date, i.e. **14.08.2025**, of Antibiotice SA, a trading company registered at the Trade Register Office under number J1991000285223, fiscal code 1973096, holding a number of _____ shares, representing _____% of the total **671,338,040** shares issued by the Company, which grant me _____ voting rights in the General Meeting of Shareholders representing _____% of the total voting rights,

being aware of the Agenda for the Ordinary General Meeting of the Shareholders *Antibiotice SA* convened on **26.08.2025**, at 10:00 am, and respectively on **27.08.2025**, at 10:00 am (in the event that the conditions for organizing the General Meeting of Shareholders will not be met on the first above-mentioned date) and being aware of the documentation provided by *Antibiotice SA* in connection with these agendas,

and in accordance with Article 208 of the ASF Regulation no. 5/2018, I hereby exercise my right to vote by mail, as follows:

No	Agenda for the Ordinary General Meeting of Shareholders	Option		
		for	against	abstention
0	1	2	3	4
1.	Approval of the project entitled "Research and Development Center Inova a+ and critical medicines production" which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program			

	Managing Authority (AMPS)”, Priority 9, “Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector” and the related expenses in value of 376,877,912.87 lei, VAT-free. Antibiotice S.A. undertakes to ensure that it has the financial capacity to provide its own contribution to both the eligible and non-eligible project expenditures, under the conditions of subsequent reimbursement/settlement of the expenses. Antibiotice S.A. undertakes, for a 5-year period from the date of completion of the investment, in accordance with the state aid scheme and the provisions of Article 65 of Regulation (EU) No. 2021/1060, to maintain the investment made by covering the related operating and maintenance costs, as well as the necessary associated services, in order to ensure its financial sustainability.			
2.	Approval of the technical and economic indicators of the project entitled “Research and Development Center Inova a+ and critical medicines production”, which will be submitted for financing under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, conducted by Health Program Managing Authority”, Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector”.			
3.	Authorization of the Management Board to issue resolutions approving, based on supporting documentation, the exact amount of expenses related to the project “Research and Development Center Inova a+ and critical medicines production” and its technical-economic indicators which will be submitted for funding under the Health Program, Project Call “Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)”, Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector, provided they are kept within the maximum value of 376,877,912.87 lei, VAT-free.			

I hereby attach:

- Certified copy of the shareholder’s ID - for individual shareholders (Identity card/passport/residence permit);
- Copy of the registration certificate for the legal persons/entities;
- Certified copy of the ID with respect to authorized agents/ attorneys-in-fact who are individuals (Identity card/passport/residence permit), if applicable;
- Special Power of Attorney for the agent/attorney-in-fact, in original (if applicable),
- The certificate of incorporation or any other document attesting to the quality of legal representative, in the case of legal entity shareholders.

Contact phone number_____

I/The undersigned, am fully and exclusively liable for the stipulations contained therein, in my capacity as shareholder of Antibiotice trading company.

Date _____

Individual shareholder

(Full name of the shareholder - in capitals)

(Shareholder's signature)

Corporate shareholder

(Name of the shareholder - in capitals)

(Full name and position of the shareholder's legal representative - in capitals)

(Seal and signature of the shareholder's legal representative)

Contact phone no. _____

Note:

(*) to be completed for entities/corporate shareholders only.

The voting form by mail will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting.

In the event of updating the Vote-by-mail form, please check the requirements in the GM Convening Notice starting with the 16th day after the publication of the Convening Notice.

After filling in and signing the Vote by mail, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice Registrar's Office by 24.08.2025, 10:00 am at the latest.